ProfileGDS5678 / 1450958_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 96% 95% 96% 94% 96% 93% 91% 94% 95% 96% 96% 97% 97% 96% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.6362496
GSM967853U87-EV human glioblastoma xenograft - Control 28.5811295
GSM967854U87-EV human glioblastoma xenograft - Control 38.9230496
GSM967855U87-EV human glioblastoma xenograft - Control 48.213694
GSM967856U87-EV human glioblastoma xenograft - Control 59.1195896
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.6169693
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.2654791
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.2457494
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.5849995
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 19.0434796
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.7244396
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 39.1918797
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 49.2016397
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 59.000396